Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Redhill Biopharma Ltd RDHL

Healthcare
RedHill Biopharma Ltd is an Israel-based specialty biopharmaceutical company primarily focused on gastrointestinal and infectious diseases. RedHill promotes the gastrointestinal drugs such as, Talicia for the treatment of Helicobacter pylori (H. pylori) infection, and Aemcolo, for the treatment of travelers’ diarrhea. RedHill’s clinical late-stage development programs include: :info: RHB-204... see more

Recent & Breaking News (NDAQ:RDHL)

RedHill Biopharma Initiates U.S. Promotion of Aemcolo® for Travelers' Diarrhea

GlobeNewswire December 17, 2019

RedHill Biopharma Reports Third Quarter 2019 Financial Results and Operational Highlights

GlobeNewswire November 19, 2019

Dual-Listed RedHill Biopharma to Voluntarily Delist from Tel-Aviv Stock Exchange

GlobeNewswire November 15, 2019

RedHill Biopharma to Host Third Quarter 2019 Financial Results Conference Call on November 19, 2019

GlobeNewswire November 13, 2019

RedHill Biopharma Announces Publication of RHB-102 Gastroenteritis Phase 3 Study Results in JAMA

GlobeNewswire November 12, 2019

RedHill Biopharma Announces FDA Approval of Talicia® for Treatment of H. pylori in Adults

GlobeNewswire November 4, 2019

RedHill Biopharma Announces FDA Approval of Talicia® for Treatment of H. pylori in Adults

Thomson Reuters ONE November 4, 2019

RedHill Biopharma to Present at the BIO-Europe 2019 Conference

GlobeNewswire October 29, 2019

RedHill Biopharma to Present New Phase 3 Data on RHB-105 and RHB-104 at the American College of Gastroenterology 2019 Annual Meeting

GlobeNewswire October 28, 2019

RedHill Biopharma Announces $36 Million Strategic Investment by Cosmo Pharmaceuticals and U.S. Rights to Approved Travelers' Diarrhea Drug AEMCOLO

GlobeNewswire October 18, 2019

RedHill Biopharma Sponsors No Stomach For Cancer's Symposium Ahead of Stomach Cancer Awareness Month

GlobeNewswire October 16, 2019

RedHill Biopharma Announces Full Results from Positive MAP US Phase 3 Study and Supportive Top-Line Results from MAP US2 Open-Label Extension Study with RHB-104 in Crohn's Disease

GlobeNewswire October 11, 2019

RedHill Biopharma Provides H2/2019 R&D Update

GlobeNewswire September 26, 2019

RedHill Biopharma to Present at Upcoming Investor Conferences in September

GlobeNewswire August 27, 2019

RedHill Biopharma Announces Acceptance of Oral Presentations on RHB-105 (H. pylori) and RHB-104 (Crohn's Disease) Phase 3 Data at ACG 2019 Annual Scientific Meeting

GlobeNewswire August 21, 2019

RedHill Biopharma Reports Second Quarter 2019 Financial Results and Operational Highlights

GlobeNewswire July 23, 2019

RedHill Biopharma Ltd. to Host Earnings Call

Accesswire July 23, 2019

RedHill Biopharma to Host Second Quarter 2019 Financial Results Conference Call on July 23, 2019

GlobeNewswire July 15, 2019

RedHill Biopharma Announces FDA Acceptance of New Drug Application for Talicia®

GlobeNewswire July 3, 2019

RedHill Biopharma Receives Allowance for New U.S. Patent Covering RHB-104 for Crohn's Disease and RHB-204 for NTM Infections

GlobeNewswire June 10, 2019